Maharaj, M.; Perrone, E.; Wirtz, R.M.; Heslop, L.; Govender, T.; Korowlay, N.A.; Ghai, K.; Parkar, T.; Baum, R.P.
Is Extraordinary Response and Long-Term Remission of Metastatic Castration-Resistant Prostate Cancer (mCRPC) After [¹⁷⁷Lu]Lu-PSMA Radioligand Therapy Due to an Immunomodulatory Effect (Radiovaccination)? A Dual Center Experience on Super-Responders. Cancers 2025, 17, 476.
https://doi.org/10.3390/cancers17030476
AMA Style
Maharaj M, Perrone E, Wirtz RM, Heslop L, Govender T, Korowlay NA, Ghai K, Parkar T, Baum RP.
Is Extraordinary Response and Long-Term Remission of Metastatic Castration-Resistant Prostate Cancer (mCRPC) After [¹⁷⁷Lu]Lu-PSMA Radioligand Therapy Due to an Immunomodulatory Effect (Radiovaccination)? A Dual Center Experience on Super-Responders. Cancers. 2025; 17(3):476.
https://doi.org/10.3390/cancers17030476
Chicago/Turabian Style
Maharaj, Masha, Elisabetta Perrone, Ralph M. Wirtz, Lucille Heslop, Trisha Govender, Nisaar A. Korowlay, Kriti Ghai, Tanay Parkar, and Richard P. Baum.
2025. "Is Extraordinary Response and Long-Term Remission of Metastatic Castration-Resistant Prostate Cancer (mCRPC) After [¹⁷⁷Lu]Lu-PSMA Radioligand Therapy Due to an Immunomodulatory Effect (Radiovaccination)? A Dual Center Experience on Super-Responders" Cancers 17, no. 3: 476.
https://doi.org/10.3390/cancers17030476
APA Style
Maharaj, M., Perrone, E., Wirtz, R. M., Heslop, L., Govender, T., Korowlay, N. A., Ghai, K., Parkar, T., & Baum, R. P.
(2025). Is Extraordinary Response and Long-Term Remission of Metastatic Castration-Resistant Prostate Cancer (mCRPC) After [¹⁷⁷Lu]Lu-PSMA Radioligand Therapy Due to an Immunomodulatory Effect (Radiovaccination)? A Dual Center Experience on Super-Responders. Cancers, 17(3), 476.
https://doi.org/10.3390/cancers17030476